The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations o...
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
About this item
Full title
Author / Creator
Alexander, Tobias , Sarfert, Ramona , Klotsche, Jens , Kühl, Anja A , Rubbert-Roth, Andrea , Lorenz, Hannes-Martin , Rech, Jürgen , Hoyer, Bimba F , Cheng, Qingyu , Waka, Aderajew , Taddeo, Adriano , Wiesener, Michael , Schett, Georg , Burmester, Gerd-Rüdiger , Radbruch, Andreas , Hiepe, Falk and Voll, Reinhard E
Publisher
England: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
ObjectivesTo investigate whether bortezomib, a proteasome inhibitor approved for treatment of multiple myeloma, induces clinically relevant plasma cell (PC) depletion in patients with active, refractory systemic lupus erythematosus (SLE).MethodsTwelve patients received a median of two (range 1–4) 21-day cycles of intravenous bortezomib (1.3 mg/m2)...
Alternative Titles
Full title
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4484251
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4484251
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2014-206016
